Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XMT-1522 in Advanced HER2-Expressing Tumors
NCT02952729Phase 1Completed
- Sponsor
- Mersana Therapeutics
- Start
- Nov 2016
- Primary completion
- Jan 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of XMT-1522 in breast cancer, gastric cancer (GC) and non-small cell lung cancer (NSCLC), sponsored by Mersana Therapeutics. Primary endpoint: Maximum tolerated dose or recommended Phase 2 dose up to 14 weeks. Started Nov 2016; status: completed.
02
Drugs
XMT-1522
03
Conditions
breast cancergastric cancer (GC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02952729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02952729.